# Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera

Source: https://onco.cc/trials/nct06033586/  
OnCo record `nct06033586` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Rusfertide in myeloproliferative neoplasms, run by Protagonist Therapeutics, Inc., active and no longer recruiting.

## Summary

Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera is a phase 3 interventional study registered as NCT06033586 by Protagonist Therapeutics, Inc., with 46 participants enrolled, started 2024-01-22 and due to reach its primary completion in 2026-04-01. Interventions recorded: Open-label rusfertide.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06033586
- Phase: 3
- Setting: An Extension Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera (THRIVE)
- Sponsor: Protagonist Therapeutics, Inc.
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT06033586: https://clinicaltrials.gov/study/NCT06033586

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [Rusfertide](https://onco.cc/drugs/rusfertide/)
- companies: [Protagonist Therapeutics](https://onco.cc/companies/protagonist-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06033586.json